I. Why the “Off-the-Shelf” Vision of CAR-NK Is Still Challenged by Cryopreservation

As CAR-T has moved toward scalable development, CAR-NK has attracted strong interest due to its potential for allogeneic use, lower GVHD risk, and broader target coverage. However, in process development research, the most painful challenge is often not cell sourcing, CAR construction, or in vitro cytotoxicity validation, but a seemingly simple step: cryopreservation and recovery.

Primary peripheral blood-derived NK cells often show sharply reduced viability, loss of CAR expression, weakened metabolic activity, and reduced target-cell killing after freezing and thawing. These issues repeatedly limit the process-side feasibility of true off-the-shelf CAR-NK workflows.

According to a study presented at ASGCT 2025, researchers used a cytokine combination called “cryokines”—IL-12, IL-15, and IL-18—for 24-hour stimulation at the late stage of CAR-NK manufacturing. After cryopreservation and recovery, cryokine-treated CAR-NK cells retained stable CAR and IL-15 transgene expression, upregulated CD25 and GLUT1, downregulated TGFβ and KIR2DL3, and displayed a cytokine-induced memory-like (CIML) phenotype.

The treated cells also showed increased mitochondrial mass and restored metabolic activity. In mouse solid tumor xenograft research, cryopreserved and recovered cells even showed stronger tumor suppression activity than freshly infused cells.

This research direction reveals an important point: interleukins are no longer just expansion reagents; they are key switches that regulate metabolic plasticity and determine post-thaw cell fate.

II. Functional Differences and Synergy Among IL-2, IL-15, and IL-21

To reproduce this type of process research in an internal workflow, interleukins should not be treated as a single category of “NK stimulants.” The three commonly used γc-family interleukins have distinct biological preferences.

2.1 IL-2

IL-2 is a classic expansion factor that can activate multiple pathways, including STAT5, AKT, and ERK. At higher doses, IL-2 may also promote Treg expansion. It is commonly used as a background interleukin in in vitro NK and T cell expansion systems.

2.2 IL-15

IL-15 shares βγ receptor subunits with IL-2, but its trans-presentation mechanism makes it more efficient than IL-2 in inducing NK and CD8 memory-like phenotypes, with less Treg bias. It is one of the most common “self-supporting” factors used in engineered CAR-NK transgene payloads.

2.3 IL-21

IL-21 is also a γc-family cytokine, but it preferentially activates STAT3. It has been reported to promote early NK precursor expansion, reduce exhaustion-associated phenotypes, and help maintain T cell stemness. When combined with IL-15 in later process stages, IL-21 can improve functional reproducibility under long-term repeated stimulation conditions.

Placed along a process timeline, these cytokines can support a simplified framework of expansion → maintenance → pre-freeze conditioning → recovery. IL-2 / IL-15 can be used in early stages to support cell number expansion; IL-15, with IL-21 as a supporting cytokine, can help maintain phenotype in the middle stage; and IL-12 / IL-15 / IL-18, or alternative combinations such as IL-15 / IL-21 depending on the internal pipeline, can be introduced at the late stage for metabolic preconditioning to improve post-thaw viability and cytotoxic function.

II.5 The Metabolic Logic Behind the CIML Phenotype

To understand why cryokine treatment helps CAR-NK cells retain cytotoxic function after thawing, the perspective must shift from “cytokines stimulating cell function” to metabolic plasticity.

The core damage caused by NK cell cryopreservation comes from three sources:

- Osmotic shock and lipid bilayer rearrangement during freeze-thaw cycles

- Metabolic shutdown at low temperature and ROS burst after thawing

- Nutrient depletion and increased apoptosis signaling under high-density late-stage process conditions

IL-15 activates mTORC1 and OXPHOS through STAT5. IL-12 promotes early glycolytic switching. IL-18 enhances the availability of metabolic substrates through NF-κB.

Together, this metabolic preconditioning combination increases mitochondrial mass, allowing cryopreserved cells to maintain enough ATP reserve at the moment of thawing to respond to cold stress and preserve functional continuity.

This mechanism is not limited to CAR-NK. CAR-T, γδT, iNKT, and other cell process research programs are also exploring pre-freeze cytokine combinations along the same logic. Biofargo IL-2 / IL-15 / IL-21 products therefore serve as high-frequency supply components for this type of process research.

III. Key Technical Parameters for Recombinant Interleukins

Interleukins are typical research reagents with high consumption and strong batch sensitivity. Once a supplier or lot changes, process research often requires a full workflow re-comparison, which can be costly.

Biofargo provides clear parameters across several key dimensions to support process-side indicator management:

- Purity
SDS-PAGE and SEC dual characterization, ≥95%. Truncated or aggregated forms in low-purity interleukins may disturb dose-response curves.

- Specific Activity / EC50
Recombinant Human IL-2 specific activity ≥1×10⁷ IU/mg is a core indicator of native-like folding. IL-15 ED50 typically falls within the 0.3–3 ng/mL range. IL-21 EC50 should be confirmed with the user’s own reporter system because it depends on the target cell type.

- Endotoxin
≤0.5 EU/mg is strongly recommended for cell process research. CAR-NK and CAR-T manufacturing research is highly sensitive to endotoxin contamination.

- Carrier and Buffer
BSA-free / animal-free options are preferred when downstream workflows need to pair the cytokine with user-defined carrier proteins and avoid introducing exogenous animal-derived signals.

- Lot-to-Lot Consistency
For process validation research, reserving 1–2 years of use from the same lot is recommended. Critical lots should be retained for future reference.

IV. Biofargo Product Portfolio

Compared with IL-2 / IL-15 / IL-21 products from global suppliers, Biofargo offers more competitive research procurement pricing while maintaining aligned specific activity parameters. For laboratories conducting long-term cell process research and frequent repeat expansion experiments, this can help reduce reagent budget pressure to a more manageable level.

IV.5 Comparative Overview (Research Procurement Perspective)

CAR-NK / CAR-T process research is characterized by high IL-2 and IL-15 consumption, long-term usage, and repeated testing across batches. Lowering unit cost to a reasonable range means research teams can allocate more budget to expensive transfection reagents, flow cytometry, and sequencing consumables instead of spending heavily on repeated expansion reagents.

V. Laboratory Recommendations (RUO Only)

- Reconstitution
Use 0.22 μm-filtered deionized water when possible. Use 0.1% BSA or HSA as a carrier to reduce protein adsorption loss. If the downstream system is serum-free, select a BSA-free buffer strategy.

- Storage
Store long-term at -80 ℃ in aliquots. Short-term storage at 4 ℃ should not exceed 1 week. Avoid repeated freeze-thaw cycles. Pre-aliquoting at single-use working concentrations is generally recommended.

- Typical Working Concentrations
IL-2 starting concentration for NK / T cell expansion: 100–300 IU/mL. IL-15 starting concentration: 5–10 ng/mL. IL-21 starting concentration: 10–25 ng/mL. A dose-response calibration is recommended whenever a new lot is introduced.

- Process Research Framework
Introduce different IL combinations at different time points during in vitro expansion, then evaluate phenotype and function across two axes. Phenotype markers may include CD25, GLUT1, and CD56bright/dim ratio; functional readouts may include K562 killing and IFN-γ release.

- Pre-Freeze Metabolic Conditioning
Perform 24-hour metabolic preconditioning before freezing and compare post-thaw viability and cytotoxicity.

- Internal Payload Synergy
For IL-15 transgene payload research, compare endogenous stimulation and exogenous cytokine stimulation to generate synergy curves.

All products mentioned are for Research Use Only and are not intended for diagnosis, treatment, prevention, or disease monitoring in humans or animals. End-use compliance should be evaluated by the customer according to applicable local regulations.

VI. Conclusion + CTA

The “off-the-shelf” research goal of CAR-NK requires process researchers to carefully design cytokine combinations across four stages: expansion, maintenance, pre-freeze conditioning, and recovery.

Biofargo IL-2, IL-15, and IL-21 research-grade proteins can serve as a stable reagent combination along this process curve, helping laboratories perform reproducible functional and phenotypic comparisons across lots and experiments.

- View IL-2

- View IL-15

- View IL-21

VII. Frequently Asked Research Questions

Q1: If a workflow uses IL-2 alone, does switching to IL-15 alone require dose recalibration?

A: Yes. IL-15 EC50 is not in the same order of magnitude as IL-2. Directly copying the IL-2 dose may cause overactivation or insufficient expansion. A dose-response study is recommended for each new lot before entering the main process workflow.

Q2: Does adding IL-12 / IL-15 / IL-18 for 24 hours before freezing create an overactivation risk?

A: In an RUO process research context, this can be monitored by flow cytometry markers such as CD25, HLA-DR, and KIR2DL3, together with functional killing assays. Most reports suggest that within a 24-hour short stimulation window, the benefits of metabolic remodeling are greater than the risk of exhaustion.

Q3: What is the role of IL-21 in NK process research?

A: IL-21 tends to promote early NK precursor expansion and help maintain stemness-associated phenotypes. When combined with IL-15, it is often associated with improved long-term reproducibility. The specific benefit should be confirmed through controlled experiments within the user’s own workflow.